Delivering Allogeneic Donor Products During COVID-19: Lessons for the Future
Description
Published in Transplantation and Cellular Therapy, Meeting the Demand for Unrelated Donors in the Midst of the COVID-19 Pandemic: Rapid Adaptations by NMDP and its Network Partners Ensured a Safe Supply of Donor Products, offers the first report on the impact of the COVID-19 pandemic on the ability of NMDP and its Network to safely deliver unrelated donor products early in the pandemic.
Despite the many unexpected challenges of the pandemic, the NMDP and its Network continued to effectively deliver domestic and unrelated donor products to allogeneic transplant patients in similar or shorter timeframes than before COVID-19. This interactive panel discussion will provide attendees with the opportunity to ask panelists questions and dive deeper into the learnings below and how they may impact the future of the field.
Learning Objectives
- An overview of the challenges faced by the transplant community during COVID-19
- Cryopreservation's role during the COVID-19 pandemic to ensure continuity of donor and patient safety and care
- Logistics navigation during the COVID-19 pandemic, including Related Donor Services, domestic vs. international product considerations, and logistical barriers overcome through partnerships at the domestic and international level
- The impact of COVID-19 on donor availability
Speakers
- Jeni Newman, Director, Case Management, NMDP
- Jeffrey Auletta, MD, Nationwide Children's Hospital
- Jeremy Pantin, MD, Sarah Cannon Center for Blood Cancer at TriStar Centennial
Questions?
Read a summary of the COVID-19 paper published in TCT Journal to learn more about how NMDP and Network partners were able to continue to effectively deliver unrelated donor products early in the pandemic.